A new therapy to re-engage the heart’s natural electrical pathways – instead of bypassing them – could mean more treatment options for heart failure patients who also suffer from electrical disturbances, such as arrhythmias, according to research led by the University of Chicago Medicine.
In a first-ever pilot study, called the His SYNC trial, researchers compared the effectiveness of two different cardiac resynchronization therapies, or treatments to correct irregularities in the heartbeat through implanted pacemakers and defibrillators. The current standard of care, known as biventricular pacing, uses two pacing impulses in both lower chambers, whereas the newer approach, called His bundle pacing, attempts to work toward engaging and restoring the heart’s natural physiology. The two approaches have never before been directly compared in a head-to-head clinical trial.
“This is the first prospective study in our field to compare outcomes between different ways to achieve cardiac resynchronization,” said cardiologist Roderick Tung, MD, FHRS, the Director of Cardiac Electrophysiology & EP Laboratories at the University of Chicago Medicine. “Through His bundle pacing, we’re trying to tap into the normal wiring of the heart and restore conduction the way nature intended. Previously, we have just accepted that we had to bypass it through pacing two ventricles at a time.”
Tung spearheaded the two-year trial with UChicago Medicine cardiologist Gaurav Upadhyay, MD, FHRS, lead author of the study. The trial involved 40 adult patients across seven institutions in the Midwest. The UChicago Medicine team served as the independent coordinating site. Results of the study were presented as a featured late-breaking trial at the Heart Rhythm Society’s annual scientific sessions in San Francisco on May 9. To qualify as a late-breaking trial, the research must be groundbreaking and unique. The study was also published in the Journal of the American College of Cardiology.
A different resynchronization method
Biventricular pacing involves implanting wires, called leads, to simultaneously pace the right and left ventricles of the heart. A pacemaker then sends a timed electric pulse to the two leads with the goal of a synchronized contraction, which closely simulates the heart’s natural heartbeat.
Nevertheless, roughly 30 percent of patients do not respond to biventricular pacing treatment, which has been shown to improve survival in clinical trials.
Tung’s team looked to see if another resynchronization method could help reduce that number by doing a clinical trial comparison between biventricular pacing and His bundle pacing. The latter involves implanting a single lead at the start of the heart’s wiring system, which then naturally branches in two to organically distribute the pacemaker’s electric pulse to both ventricles.
“Permanent His bundle pacing has been around for almost 20 years, but until now there hasn’t been randomized clinical trials on how it compares to biventricular pacing,” Tung said.
For the His SYNC trial, all of the patients met the current guidelines for receiving cardiac resynchronization therapy and were randomly selected to receive either a His bundle pacer or a coronary sinus lead for biventricular pacing. Patients weren’t told which treatment they received.
While the results of the preliminary study did not demonstrate superiority with His-CRT, Tung and his team believe a His bundle pacing approach showed comparable rates of response, warranting further study. The research was limited by a high crossover rate, which was required by the study’s protocol if an adequate lead placement could not be achieved. Nearly half of the patients selected to receive His bundle pacing had to eventually be treated with traditional biventricular pacing due to having a condition called interventricular conduction delay (IVCD). The implantation tools have also not been refined since their introduction 10 years ago.
“We need to learn how to better identify patients who cannot and will not respond to His bundle pacing,” Tung said. “During this pilot study, we learned that the net was cast too wide, and patients with IVCD can’t be corrected and improved by His bundle pacing. His SYNC II, our planned follow-up study, will specifically exclude these patients and this is perhaps the most valuable lesson from the pilot, in addition to estimated treatment effect size.”
In addition, 26 percent of patients chosen to receive biventricular pacing did not, usually because a lead could not be inserted due to the condition of their veins dictated by strict criteria to optimize implantation of left ventricular leads.
Comparing the two approaches
After six months, researchers compared the electrical synchronization and structural function of the two patient groups’ hearts. Although they expected His bundle pacing to be superior, they found no overall significant differences in the two groups, with comparable rates of electrical resynchronization and echocardiographic response.
After one year, there were no differences in the number of hospitalizations or deaths.
Noting the pilot study was limited by its size, Tung says the results indicate further investigation is needed.
“Pilot studies are never meant to be conclusive,” he said. “They’re meant to inform us about effect size, safety and feasibility to help select appropriate patients and power larger studies.”
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failureon December 13, 2019 at 9:19 pm
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved ...
- ARNI for Heart Failure: Earlier Is Betteron December 13, 2019 at 3:41 pm
Earlier is better for the initiation of angiotensin receptor-neprilysin inhibition (ARNI) therapy in people hospitalized for acute decompensated heart failure (ADHF), according to data from the ...
- Heart Failure Treatment Market Size 2019 Global Industry Share, Growth, Trend, Demand, Top Players, Opportunities and Forecast to 2024on December 13, 2019 at 12:06 am
Dec 13, 2019 (AmericaNewsHour) -- Growth forecast report " Heart Failure Treatment Market size by Product Type (Drug Treatment and Surgical Treatment), By Application (Acute Heart Failure and Chronic ...
- Study: Secondhand smoke increases heart disease risk in childrenon December 12, 2019 at 10:17 pm
More research is needed to determine how vaping and e-cigarettes affect heart disease risks in children and teens, the study authors said. RELATED CDC: U.S. cigarette smoking hit all-time low, while e ...
- Clinical Data from Reprieve Cardiovascular's Successful First-in-Human Therapy for Acute Heart Failure Presentedon December 12, 2019 at 9:11 pm
Dec. 13, 2019 /PRNewswire/ -- Reprieve Cardiovascular ®, a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF), today ...
- Aspirin Risks Outweigh Benefits for Adults With No Heart Disease Historyon December 12, 2019 at 2:26 pm
Aspirin thins the blood and helps prevent clots from forming, which can be lifesaving in the event of a heart attack or stroke. This is why doctors often prescribe a low-dose aspirin regimen to people ...
- Heart Disease Linked to Gene Variant in Africans Is Often Overlookedon December 12, 2019 at 1:21 pm
A genetic variant found in about 3 percent of individuals of African ancestry appears to be associated with high rates of heart failure caused from a rare disease significantly under-recognized and ...
- The Link Between Cancer and Heart Diseaseon December 12, 2019 at 5:03 am
When you’re facing down cancer, heart disease isn’t top of mind. Yet, it turns out many cancer patients face a greater risk from cardiovascular Dr. Jordan Ray disease (CVD) than from their cancer.
- A genetic mutation is associated with increased risk of heart failure in black people, study findson December 11, 2019 at 2:44 pm
An underdiagnosed genetic mutation in people of African descent carries an increased risk for heart failure, according to a new study. When present in those patients, a genetic variant, TTR V122I, ...
- Low-dose aspirin may not reduce heart disease risk for everyoneon December 11, 2019 at 5:01 am
Dec. 11 (UPI) --For decades, taking low-dose aspirin daily has been considered a safe and effective way of reducing risk for heart attack, stroke and heart disease. Now, the findings of a new study ...
via Bing News